Advanced Bitcoin Technologies AG Q3 FY2024 Earnings Call

· Earnings call transcript and AI-powered summary

  • Overall Performance: Organic sales growth reached 8.2% excluding COVID testing, with adjusted EPS of $1.21. Company maintains full-year EPS guidance and raised it for the third time this year. Gross margin improved to 56.3%, continuing toward a 75 bps full-year improvement.
  • Nutrition: Sales increased 3.5% YoY. U.S. Pediatric Nutrition up 12%, and Adult Nutrition up 11.5%. International pediatric segment underperformed due to commercial execution issues, but corrective actions taken mid-quarter are showing promising early results.
  • Diagnostics: Core Lab Diagnostics increased 4.5% YoY (ex-COVID). International Core Lab excluding China grew double digits. China softness attributed to Volume-Based Procurement (VBP) policy implementation. Strong growth continues in Rapid and Point-of-Care, aided by respiratory testing demand and Big Ten blood donation partnership.
  • Established Pharmaceuticals (EPE): Sales climbed 7%. Double-digit growth in Latin America, Southeast Asia, and the Middle East. Strong demand in therapeutic areas including gastroenterology, cardiometabolic, CNS, and pain management. Biosimilar launch expected in emerging markets in late 2025.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good day, and thank you for standing by. Welcome to Abbott's Third Quarter 2024 Earnings Conference Call. All participants will be able to listen only until the question-and-answer portion of this call. [Operator Instructions] This call is being recorded by Abbott. With the exception of any participant's questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. I would now like to introduce Mr. Mike Comilla, Vice President, Investor Relations. Mike Comilla: Good morning, and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer; and Phil Boudreau, Executive Vice President, Finance and Chief Financial Officer. Robert and Phil will provide opening remarks. Following their comments, we'll take your questions. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2024. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, to our annual repo

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional